Linezolid Krka (Linezolid)

Linezolid is indicated for serious Gram‑positive bacterial infections.

• MRSA infections: effective against skin and soft‑tissue infections caused by methicillin‑resistant Staphylococcus aureus.
• VRE infections: treats infections caused by vancomycin‑resistant Enterococcus species.
• Community‑acquired bacterial pneumonia: provides bacterial clearance in adult patients with pneumonia due to susceptible Gram‑positive organisms.
• Skin and soft‑tissue infections caused by susceptible Gram‑positive bacteria: resolves infection and prevents progression.

• Linezolid binds to the 50S ribosomal subunit of susceptible bacteria, preventing the formation of the initiation complex required for protein synthesis. This inhibition halts bacterial growth, rendering the organism unable to produce essential proteins, leading to a bacteriostatic effect against Gram‑positive pathogens.

Linezolid may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Diarrhea: loose stools, often self‑limiting.
• Headache: transient cranial discomfort.
• Metallic taste: altered taste perception.

Serious or Rare Side Effects

• Thrombocytopenia: significant drop in platelet count.
• Peripheral neuropathy: nerve damage causing tingling or numbness.
• Serotonin syndrome: potentially life‑threatening reaction when combined with serotonergic agents.

Before initiating therapy, clinicians should consider several safety aspects.

• Renal function: assess and adjust in severe renal impairment.
• Hepatic function: monitor liver enzymes during treatment.
• Concomitant serotonergic agents: avoid due to risk of serotonin syndrome.
• Hematologic monitoring: perform regular blood‑count checks.
• Pregnancy and lactation: safety not established; use only if benefit outweighs risk.
• Store at room temperature: keep in original container, protect from light and moisture.

Linezolid interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid)

• MAO inhibitors: risk of severe hypertension and serotonin syndrome.
• SSRIs/SNRIs: increased potential for serotonin syndrome.
• Rifampin: may markedly reduce linezolid plasma concentrations.

Moderate Interactions (Monitor Closely)

• Warfarin: possible alteration of INR, requiring monitoring.
• Oral contraceptives: reduced efficacy, consider alternative contraception.
• CYP450 inducers (e.g., carbamazepine): may lower linezolid levels, monitor therapeutic response.